Swiss National Bank Buys Shares of 22,100 Septerna, Inc. $SEPN

Swiss National Bank bought a new position in Septerna, Inc. (NASDAQ:SEPN) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,100 shares of the company’s stock, valued at approximately $531,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SEPN. Deutsche Bank AG grew its holdings in shares of Septerna by 5.3% in the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after buying an additional 744 shares during the period. Global Retirement Partners LLC acquired a new stake in Septerna during the 4th quarter worth $35,000. JPMorgan Chase & Co. raised its stake in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after buying an additional 1,315 shares during the period. PharVision Advisers LLC lifted its holdings in Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after acquiring an additional 1,780 shares in the last quarter. Finally, Nuveen LLC lifted its holdings in Septerna by 7.7% during the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after acquiring an additional 1,837 shares in the last quarter.

Insider Buying and Selling

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the sale, the insider owned 793 shares in the company, valued at $27,897.74. This trade represents a 73.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Daniel D. Long sold 3,333 shares of Septerna stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $34.36, for a total transaction of $114,521.88. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,312,716.32. This trade represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 44,494 shares of company stock worth $1,469,391. Company insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SEPN shares. Raymond James Financial increased their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Septerna in a research note on Wednesday, July 1st. Guggenheim lowered their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Finally, Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.89.

Septerna Stock Performance

NASDAQ:SEPN opened at $34.45 on Friday. Septerna, Inc. has a 52-week low of $10.62 and a 52-week high of $38.04. The company has a market cap of $1.55 billion, a P/E ratio of -42.53 and a beta of 2.29. The stock’s 50-day simple moving average is $33.58 and its 200 day simple moving average is $28.58.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, equities analysts predict that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.